Previous researches have proved that EZH2 is capable of regulating cell proliferation in larynx carcinoma through targeting RUNX3 via the Wnt /β-catenin signaling pathway [5]; EZH2 inhibitors are capable of activating RUNX3 and up-regulating the expressions of SETDB1 and ΔNp63α, thus antagonizing the phenotype of esophageal squamous cell carcinoma [6]. This evidence concerns the gene RUNX3 and laryngeal carcinoma.